ArticleNature communications2025
Universal peptide synthesis via solid-phase methods fused with chemputation.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery.Journal of the American Chemical Society · 2026Article
- A Comprehensive Review on the Anticancer Activity of Plant Peptides and Their Mechanisms of Action.Foods (Basel, Switzerland) · 2026Review
- Programmable Microwaveable Chemistry in the Chemputer.Angewandte Chemie (International ed. in English) · 2026Article
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since the advent of automated solid-phase peptide synthesis (SPPS), many commercial platforms have been developed, facilitating cutting-edge research across many biochemical fields. However, despite considerable technological advancements, these systems remain limited in flexibility and chemical capability. Herein, we present a fully automated programmable platform that combines the efficiency of SPPS with the chemical flexibility of a Chemical Processing Unit (Chemputer). SPPS protocols, from resin swelling to peptide precipitation, are captured and automated using the Chemical Description Language (χDL), affording peptide sequences in high purity (>79%) and on a multi-milligram scale. Owing to the modularity of the platform, valuable transformations are integrated into the workflow, including ring-closing metathesis, copper-catalyzed azide-alkyne cycloaddition, and native chemical ligation. These tailored modifications are carried out in one, uninterrupted synthetic protocol, performing up to 1635-unit operations, executed over 85 h of activity, producing peptides such as GHRH(1-29), Semaglutide, and Capitellacin, finally unlocking bottlenecks in automated SPPS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.